Beiersdorf Ag (BDRFF) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to Biosdorf's first quarter conference call. Thank you for joining us today. I'm here with our CEO, Vincent Warnery, as well as our CFO, Astrid Herrmann. We would like to share with you Biosdorf's sales performance of the first three months of 2025. We will start with a presentation of our results, followed by a Q&A session. And with that, I'd like to hand over to Vincent. Thank you, Christopher, and good morning. Welcome to today's conference call. Astrid and I will now guide you through our sales figures for the first three months of 2025. Following a very strong performance in 2024, Basel delivered against expectations in the first quarter of the new financial year. Our first quarter's results are influenced by a strong prior year base and support our outlook for the full year. Our derma business deserves again a special mention as we continue to see a strong performance. Eucerin delivers not only in our established markets, but also expands successfully into new countries. At the same time, we are setting the foundation for our future success in China. With proactive measures, we are refocusing on EVA business to win in skincare with strategic innovations in these key markets. Delivering breakthrough innovation across our brands and expanding into more wide spaces remained the key driver of our growth of our first quarter results. In the first quarter, we delivered plus 2.3% organic sales growth in our consumer segment against a high-priority baseline, despite the stocking measures due to ongoing challenges in the travel retail market and in the face of a strategic repositioning in China. Excluding China, our consumers' business grew by 4% organically, which is within the range of the full-year guidance. Nivea sales increased by 2.5% comp...